Pharmaceutical Giant Novartis Challenges India’s Patent Laws, Threatening Delivery of AIDS Drugs to Tens of Thousands

For indispensable reporting on the coronavirus crisis and more, subscribe to Mother Jones' newsletters.


The pharmaceutical industry once again stirs a witches’ brew, reports New Scientist, challenging patent laws that have enabled India to supply AIDS drugs to poor patients worldwide.

India’s generic drugs form the backbone of MSF’s [Medecins Sans Frontieres/Doctors without Borders] AIDS programmes, in which 80,000 people in 30 countries receive treatment.

“We are reaching a quarter of the people who need antiretroviral treatment in sub-Saharan Africa,” says Ivy Mwangi, an MSF doctor. “Rapid scale-up in treatment is only possible with the availability and affordability of generic drugs, most of which are produced in India.”

But Swiss pharma-giant Novartis is whinging that financial hegemony is the only sure road to drug innovation, and that India should not be allowed to provide generics for people who can’t pay $10,000 a year for its drugs.

“If Novartis gets through with its case our lives are at risk,” Monique Wanjala, a woman who has been living with HIV for 13 years, told a news conference in Nairobi. “We want this case dropped,” she said. “If we die because affordable generic drugs aren’t available, where will they sell the drug? If profits are going to be put before peoples’ lives then we have a serious problem.”

THE BIG PICTURE

You expect the big picture, and it's our job at Mother Jones to give it to you. And right now, so many of the troubles we face are the making not of a virus, but of the quest for profit, political or economic (and not just from the man in the White House who could have offered leadership and comfort but instead gave us bleach).

In "News Is Just Like Waste Management," we unpack what the coronavirus crisis has meant for journalism, including Mother Jones’, and how we can rise to the challenge. If you're able to, this is a critical moment to support our nonprofit journalism with a donation: We've scoured our budget and made the cuts we can without impairing our mission, and we hope to raise $400,000 from our community of online readers to help keep our big reporting projects going because this extraordinary pandemic-plus-election year is no time to pull back.

THE BIG PICTURE

You expect the big picture, and it's our job at Mother Jones to give it to you. And right now, so many of the troubles we face are the making not of a virus, but of the quest for profit, political or economic (and not just from the man in the White House who could have offered leadership and comfort but instead gave us bleach).

In "News Is Just Like Waste Management," we unpack what the coronavirus crisis has meant for journalism, including Mother Jones’, and how we can rise to the challenge. If you're able to, this is a critical moment to support our nonprofit journalism with a donation: We've scoured our budget and made the cuts we can without impairing our mission, and we hope to raise $400,000 from our community of online readers to help keep our big reporting projects going because this extraordinary pandemic-plus-election year is no time to pull back.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.